Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Jan 4, 2022

Keywords

ClinConnect Summary

The Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!) is a clinical trial aimed at helping patients with breast cancer, melanoma, and gastrointestinal neuroendocrine tumors. The study focuses on understanding if we can detect signs of cancer returning (called molecular residual disease, or MRD) before it becomes visible on scans or causes symptoms. By collecting and analyzing samples of blood, stool, and tissue from patients who have already undergone treatment, researchers hope to identify these early signs of relapse. This could lead to earlier interventions and potentially longer periods without cancer returning.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of a solid tumor that is either early-stage or locally advanced and has been treated or is planned for curative treatment. All participants will need to provide informed consent, confirming that they understand the study and agree to take part. There are no specific exclusions based on other health conditions, making it open to a wide range of patients. If you join the trial, you can expect to provide samples and possibly receive more frequent monitoring, which could help in catching any signs of cancer returning early.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with histological confirmation of a solid tumor.
• • 2. Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
• • 3. Patient must be ≥ 18 years old.
• • 4. All patients must have signed and dated an informed consent form.
• Exclusion Criteria:
• • None